A phase 2 trial of all-trans-retinoic acid in combination with interferon-α2a in children with recurrent neuroblastoma or wilms tumor: A pediatric oncology branch, NCI and children's oncology group study

Pediatric Blood and Cancer

Volumn 49, Issue 5, 2007, Pages 661-665

  Adamson, Peter C ^a   Matthay, Katherine K ^b   O'Brien, Michelle ^c   Reaman, Gregory H ^d   Sato, Judith K ^e   Balis, Frank M ^c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Interferon; Neuroblastoma; Phase 2; Retinoic acid; Wilms tumor

Indexed keywords

ALPHA2A INTERFERON; CATECHOLAMINE; DOPAMINE; DOXORUBICIN; HOMOVANILLIC ACID; ISOTRETINOIN; RETINOIC ACID; VANILMANDELIC ACID;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEVER; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOSTIMULATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROBLASTOMA; NEUROBLASTOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; DRUG COMBINATION; INFANT; METHODOLOGY; PRESCHOOL CHILD; REMISSION; SALVAGE THERAPY; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HUMANS; INFANT; INTERFERON ALFA-2A; NEUROBLASTOMA; REMISSION INDUCTION; SALVAGE THERAPY; TREATMENT OUTCOME; TRETINOIN; WILMS TUMOR;

EID: 35148882962     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21011     Document Type: Article

References (52)

1. Smith MA, Parkinson DR, Cheson BD, et al. Retinoids in cancer therapy. J Clin Oncol 1992;10:839-864.
2. Moasser MM, Motzer RJ, Khoo KS, et al. All-trans retinoic acid for treating germ cell tumors: In vitro activity and results of a phase II trial. Cancer 1995;76:680-686.
3. Treat J, Friedland D, Luginbuhl W, et al. Phase II trial of all-trans retinoic acid in metastatic non-small cell lung cancer. Cancer Invest 1996;14:415-420.
4. Trump DL, Smith DC, Stiff D, et al. A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: A clinical trial with detailed pharmacokinetic analysis. Cancer Chemother Pharmacol 1997;39:349-356.
5. Berg WJ, Schwartz LH, Amsterdam A, et al. A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest New Drugs 1997;15:353-355.
6. Culine S, Kramar A, Droz JP, et al. Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer. J Urol 1999;161:173-175.
7. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 1990;50:3473-3486.
8. Bollag W. Retinoids and interferon: A new promising combination? Br J Haematol 1991;79:87-91.
9. Frey JR, Peck R, Bollag W. Antiproliferative activity of retinoids, interferon alpha and their combination in five human transformed cell lines. Cancer Lett 1991;57:223-227.
10. Gallagher RE, Lurie KJ, Leavitt RD, et al. Effects of interferon and retinoic acid on the growth and differentiation of clonogenic leukemia cells from acute myelogenous leukemia patients treated with recombinant leukocyte-αA interferon. Leuk Res 1987;11: 609-619.
11. Higuchi T, Hannigan GE, Malkin D, et al. Enhancement by retinoic acid and dibutyryl cyclic adenosine 3′:5′-monophosphate of the differentiation and gene expression of human neuroblastoma cells induced by interferon. Cancer Res 1991;51:3958-3964.
12. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis-Retinoic acid and interferon alpha-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;84:235-241.
13. Lippman SM, Kavanagh JJ, Paredes EM, et al. 13-cis-Retinoic acid plus interferon alpha-2a: Highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992; 84:241-245.
14. Voravud N, Lippman SM, Weber RS, et al. Phase II trial of 13-cis-retinoic acid plus interferon-alpha in recurrent head and neck cancer. Invest New Drugs 1993;11:57-60.
15. Dhingra K, Papadopoulos N, Lippman S, et al. Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma. Invest New Drugs 1993;11:39-43.
16. Arnold A, Ayoub J, Douglas L, et al. Phase II trial of 13-cis-retinoic acid plus interferon alpha in non-small-cell lung cancer. JNCI 1994;86:306-309.
17. Athanasiadis I, Kies MS, Miller M, et al. Phase II study of all-trans-retinoic acid and α-Interferon in patients with advanced non-small cell lung cancer. Clin Cancer Res 1995;1:973-979.
18. Escudier B, Ravaud A, Berton D, et al. Phase II study of interferon-alpha and all-trans retinoic acid in metastatic renal cell carcinoma. J Immunother 1998;21:62-64.
19. Brembeck FH, Schoppmeyer K, Leupold U, et al. A phase II pilot trial of 13-cis retinoic acid and interferon-alpha in patients with advanced pancreatic carcinoma. Cancer 1998;83:2317-2323.
20. Sondak VK, Liu PY, Flaherty LE, et al. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: A Southwest Oncology Group study. Cancer J Sci Ain 1999; 5:41-47.
21. Enzinger PC, Ilson DH, Saltz LB, et al. Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma. Cancer 1999;85:1213-1217.
22. Adamson PC, Reaman G, Finklestein JZ, et al. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol 1997;15: 3330-3337.
23. Bailey J, Pluda JM, Foli A, et al. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. J Clin Oncol 1995; 13:1966-1974.
24. Adamson PC, Bailey J, Pluda J, et al. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol 1995;13:1238-1241.
25. Adamson PC, Balis FM, Yarchoan R, et al. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. Proc Am Assoc Cancer Res 1993;34:212.
26. Adamson PC, Boylan JF, Balis FM, et al. Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Res 1993;53:472-476.
27. Sidell N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst 1982;68:589-596.
28. Abemayor E, Chang B, Sidell N. Effects of retinoic acid on the in vivo growth of human neuroblastoma cells. Cancer Lett 1990;55: 1-5.
29. Abemayor E, Sidell N. Human neuroblastoma cell lines as models for the in vitro study of neoplastic and neuronal cell differentiation. Environ Health Perspect 1989;80:3-15.
30. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985;313:404-406.
31. Thiele CJ, Deutsch LA, Israel MA. The expression of multiple proto-oncogenes is differentially regulated during retinoic acid induced maturation of human neuroblastoma cell lines. Oncogene 1988;3:281-288.
32. Lucarelli E, Kaplan D, Matsumoto K, et al. Retinoic acid induced differentiation is mediated by trkB receptors. Prog Clin Biol Res 1994;385:185-198.
33. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
34. Vincent TS, Re GG, Hazen-Martin DJ, et al. All-trans-retinoic acid-induced growth suppression of blastemal Wilms' tumor. Pediatr Pathol Lab Med 1996;16:777-789.
35. Takahashi M, Yang XJ, Lavery TT, et al. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features. Cancer Res 2002;62:6598-6605.
36. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979. 45 p.
37. Guidelines for reporting adverse drug reactions. In: National Cancer Institute- Cancer Therapy Evaluation Program Division of Cancer Treatment, editor. National Cancer Institute: Investigator's Handbook. Bethesda: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health; 1993. p Appendix XII.
38. 2000. Neuroblastoma (PDQ®) Treatment Statement for Health Professionals. CancerNet, National Cancer Institute ≤http://cancernet.nci. nih.gov/≥. Accessed.
39. Bleyer WA, Murphy SB, Kreissman S, et al. 2000. Children's Oncology Group Protocol: Phase III randomized study of purged versus unpurged peripheral blood stem cell transplantation following dose intensive induction chemotherapy in patients with newly diagnosed high risk neuroblastoma (CCG-3973). Protocol ID CCG-3973. Cancer Net, National Cancer Institute ≤http://cancernet.nci.nih. gov/≥. Accessed.
40. Reynolds CP, Matthay KK, Villablanca JG, et al. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003;197:185-192.
41. Reynolds CP, Schindler PF, Jones DM, et al. Comparison of 13-cis-retinoic acid to trans-retinoic acid using human neuroblastoma cell lines. Prog Clin Biol Res 1994;385:237-244.
42. Reynolds CP, Kane DJ, Einhorn PA, et al. Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res 1991;366:203-211.
43. Matthay KK, Reynolds CP. Is there a role for retinoids to treat minimal residual disease in neuroblastoma?. Br J Cancer 2000;83:1121-1123.
44. Kohler JA, Imeson J, Ellershaw C, et al. A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy. Br J Cancer 2000;83:1124-1127.
45. Gudas LJ. Retinoids and vertebrate development. J Biol Chem 1994;269:15399-15402.
46. Helson L, Helson C. Human neuroblastoma cells and 13-cis-retinoic acid. J Neurooncol 1985;3:39-41.
47. Finklestein JZ, Krailo MD, Lenarsky C, et al. 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: Report from the Childrens Cancer Study Group. Med Pediatr Oncol 1992;20:307-311.
48. Armstrong JL, Ruiz M, Boddy AV, et al. Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. Br J Cancer 2005;92:696-704.
49. Armstrong JL, Redfern CP, Veal GJ. 13-cis retinoic acid and isomerisation in paediatric oncology - Is changing shape the key to success? Biochem Pharmacol 2005;69:1299-1306.
50. Garaventa A, Luksch R, Lo Piccolo MS, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003;9:2032-2039.
51. Zirn B, Samans B, Spangenberg C, et al. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene 2005; 24:5246-5251.
52. Zirn B, Hartmann O, Samans B, et al. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int J Cancer 2006;118:1954-1962.